AAAAAA
Results:
1-11
|
Results: 11
Authors:
Bokemeyer, C
Gillis, AJM
Pompe, K
Mayer, F
Metzner, B
Schleucher, N
Schleicher, J
Pflugrad-Jauch, G
Oosterhuis, JW
Kanz, L
Looijenga, LHJ
Citation: C. Bokemeyer et al., Clinical impact of germ cell tumor cells in apheresis products of patientsreceiving high-dose chemotherapy, J CL ONCOL, 19(12), 2001, pp. 3029-3036
Authors:
Rick, O
Bokemeyer, C
Beyer, J
Hartmann, JT
Schwella, N
Kingreen, D
Neureither, S
Metzner, B
Casper, J
Wandt, H
Hartmann, F
Schmoll, HJ
Derigs, G
Gerl, A
Berdel, WE
Kanz, L
Siegert, W
Citation: O. Rick et al., Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer, J CL ONCOL, 19(1), 2001, pp. 81-88
Authors:
Atzpodien, J
Kirchner, H
Illiger, HJ
Metzner, B
Ukena, D
Schott, H
Funke, PJ
Gramatzki, M
von Jurgensom, S
Wandert, T
Patzelt, T
Reitz, M
Citation: J. Atzpodien et al., IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastaticrenal cell carcinoma: long-term results of a controlled randomized clinical trial, BR J CANC, 85(8), 2001, pp. 1130-1136
Authors:
Hanel, M
Kroger, N
Hoffknecht, MM
Peters, SO
Metzner, B
Fiedler, F
Braumann, D
Schubert, JC
Illiger, HJ
Hanel, A
Kruger, WH
Zeller, W
Weh, HJ
Hossfeld, DK
Zander, AR
Citation: M. Hanel et al., ASHAP - an effective salvage therapy for recurrent and refractory malignant lymphomas, ANN HEMATOL, 79(6), 2000, pp. 304-311
Authors:
Sezer, O
Possinger, K
Metzner, B
Illiger, HJ
Wattad, M
Heit, W
Fuss, H
Citation: O. Sezer et al., Optimal CD34(+) cell dose in autologous peripheral-blood stem-cell transplantation, J CL ONCOL, 18(18), 2000, pp. 3319-3319
Authors:
Kroger, N
Zabelina, T
Sonnenberg, S
Kruger, W
Renges, H
Stute, N
Finkenstein, F
Mayer, U
Holstein, K
Fiedler, W
Colberg, H
Sonnen, R
Kuse, R
Braumann, D
Metzner, B
del Valle, F
Erttmann, R
Kabisch, H
Zander, AR
Citation: N. Kroger et al., Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia, BONE MAR TR, 26(7), 2000, pp. 711-716
Authors:
Metzner, B
Hofmann, C
Heinemann, C
Zimpfer, U
Schraufstatter, I
Schopf, E
Norgauer, J
Citation: B. Metzner et al., Overexpression of CXC-chemokines and CXC-chemokine receptor type II constitute an autocrine growth mechanism in the epidermoid carcinoma cells KB andA431, ONCOL REP, 6(6), 1999, pp. 1405-1410
Authors:
Bokemeyer, C
Kollmannsberger, C
Meisner, C
Harstrick, A
Beyer, J
Metzner, B
Hartmann, JT
Schmoll, HL
Einhorn, L
Kanz, L
Nichols, C
Citation: C. Bokemeyer et al., First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis, J CL ONCOL, 17(11), 1999, pp. 3450-3456
Authors:
Metzner, B
Dirks, R
Gebauer, W
Reschke, D
Muller, TH
Ost, E
Reichert, D
Rosien, B
del Valle, F
Zirpel, I
Hellkamp, J
Kohse, KP
Schunter, F
Illiger, HJ
Citation: B. Metzner et al., Early infectious complications after high-dose-therapy and autologous blood stem cell transplantation, ONKOLOGIE, 22(6), 1999, pp. 491-496
Authors:
Bokemeyer, C
Kollmannsberger, C
Harstrick, A
Beyer, J
Gerl, A
Casper, J
Metzner, B
Hartmann, JT
Schmoll, HJ
Kanz, L
Citation: C. Bokemeyer et al., Treatment of patients with cisplatin-refractory testicular germ-cell cancer, INT J CANC, 83(6), 1999, pp. 848-851
Authors:
Bokemeyer, C
Harstrick, A
Beyer, J
Metzner, B
Ruther, U
Hartmann, JT
Holstein, K
Derig, HG
De Wit, R
Casper, J
Schoffski, P
Kuhrer, I
Illiger, HJ
Kempf, B
Reichle, A
Foller, A
Hossfeld, DK
Fischer, JT
Berdel, WE
Gerhartz, HH
Kirchner, H
Pfluger, KH
Ostermann, H
Kanz, L
Schmoll, HJ
Citation: C. Bokemeyer et al., The use of intensive chemotherapy for non-seminomatous testicular germ cell tumors, EUROCANCER 98, 1998, pp. 321-323
Risultati:
1-11
|